日本脑炎疫苗抗体持久性、加强免疫能力及不同种类疫苗互换性的系统评价与剂量反应Meta分析
该系统评价与剂量反应Meta分析共纳入27项研究、4558名参与者,评估日本脑炎疫苗基础免疫后抗体持久性、加强免疫能力及不同疫苗种类互换性;基础免疫后1年血清阳性率为83.4%,5年时仍稳定在82.7%;加强后10天血清阳性率达96.9%,并可维持>95%至6年;基础免疫为灭活鼠脑疫苗后使用不同种类疫苗加强有效且耐受良好,但新型疫苗互换性数据缺乏。
要点
- 基础免疫后1年血清阳性率83.4%,5年时仍稳定在82.7%。
- 加强后10天血清阳性率达96.9%,维持>95%至6年。
- 基础免疫为灭活鼠脑疫苗后换用不同种类疫苗加强有效且耐受良好。
核心结论
- 基础免疫后接种加强剂有效,7年后可能需要进一步加强。
- 基础免疫为灭活鼠脑疫苗后使用较新型疫苗加强有效且安全,但新型疫苗种类互换性数据缺乏。
研究设计与样本
- 系统检索PubMed、Embase和Cochrane CENTRAL自建库至2021年3月的文献。
- 共纳入27项研究、4558名参与者,其中11项评估抗体持久性、14项评估加强免疫能力、8项评估疫苗种类互换性。
主要发现
- 基础免疫后1年合并血清阳性率为83.4%(95%CI 78.2-89.5%),并稳定维持至5年(82.7%;95%CI 76.1-89.4%)。
- 加强后10天观察到快速回忆应答,血清阳性个体比例达96.9%(95%CI 95.9-97.8%),并维持>95%至6年。
- 基础免疫为灭活鼠脑疫苗后使用不同种类疫苗加强有效(即血清阳性率99%)且耐受良好。
关键数值与推荐
- 基础免疫后1年合并血清阳性率83.4%(95%CI 78.2-89.5%),5年时82.7%(95%CI 76.1-89.4%)。
- 加强后10天血清阳性率96.9%(95%CI 95.9-97.8%),维持>95%至6年。
- 灭活鼠脑疫苗基础免疫后不同种类疫苗加强的血清阳性率为99%。
临床怎么用
- 基础免疫后接种加强剂有效,7年后可能需要进一步加强。
- 基础免疫为灭活鼠脑疫苗后使用较新型疫苗加强有效且安全,但新型疫苗种类互换性数据缺乏。
局限性
- 新型疫苗种类互换性相关数据缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The burden of Japanese encephalitis (JE) is substantial and is arguably one of the most serious viral encephalitic diseases with high case fatality and no specific treatment. JE vaccines are the only available mean to prevent the disease; however, the long-term persistence of antibodies, boostability, and interchangeability between different vaccine classes are not well understood. METHODS: To summarise the evidence, PubMed, Embase, and Cochrane CENTRAL were systematically searched from their inception to March 2021. Dose-response meta-analysis was utilised to synthesise the proportion of individuals who were seropositive over time after a primary vaccination course and a booster dose. Proportion meta-analysis was conducted to estimate the proportion of individuals who were seropositive as well as those who reported adverse events following a booster dose with a different vaccine class. RESULTS: Of 1053 publications retrieved, 27 studies with 4,558 participants were included. Of these, 11 studies assessed persistence of antibodies, 14 studies boostability, and 8 vaccine class interchangeability. The pooled seropositivity, 1-year after primary vaccination was 83.4% (95 %CI 78.2-89.5%) and remained stable for up to 5 years (82.7%; 95 %CI 76.1-89.4%). Rapid anamnestic response was observed 10 days post-booster dose, the proportion of individuals who were seropositive reached 96.9% (95 %CI 95.9-97.8%) and remained > 95% for up to 6 years. Inactivated mouse brain-derived vaccines followed by a booster dose of a different vaccine class was effective (i.e. seropositive 99%) and well tolerated. CONCLUSIONS: A booster dose after the primary vaccination is effective and further booster doses may be needed after 7 years. Inactivated mouse brain-derived vaccine followed by a booster with a newer vaccine class is effective and safe; although, there is a paucity of data related to newer classes of vaccines interchangeability.
引用
- Islam N, Xu C, Lau CL, et al. Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis. Vaccine. 2022. PMID: 35568587. doi:10.1016/j.vaccine.2022.04.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。